Atlas Trials

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Clinical trial NCT04782804 · UNKNOWN

Trial details

NCT number
NCT04782804
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Cholangiocarcinoma, Intrahepatic
Start date
2021-01-01
Primary completion
2023-12-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.